Causeway Capital Management LLC Increases Position in Sanofi $SNY

Key Points

• Causeway Capital Management LLC raised its position in Sanofi by 16.6% in Q3, adding 139,678 shares to hold 979,317 shares worth about $46.22 million.
• Sanofi shares opened at $44.35 and trade in a 52‑week range of $43.34–$60.12; the company has a market cap of $108.17 billion, a P/E of 12.32 and a beta of 0.45.
• Analyst sentiment is mixed — recent downgrades from Bank of America and Guggenheim contrast with Deutsche Bank’s buy — leaving a consensus rating of Hold and an average price target of $62.67.

Causeway Capital Management LLC raised its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 16.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 979,317 shares of the company's stock after buying an additional 139,678 shares during the period. Causeway Capital Management LLC's holdings in Sanofi were worth $46,224,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Financial Consulate Inc. acquired a new position in Sanofi during the 3rd quarter worth about $26,000. First Horizon Corp acquired a new position in Sanofi in the 3rd quarter valued at about $33,000. Salomon & Ludwin LLC increased its stake in Sanofi by 1,046.3% during the third quarter. Salomon & Ludwin LLC now owns 768 shares of the company's stock worth $39,000 after purchasing an additional 701 shares during the period. Traub Capital Management LLC acquired a new stake in shares of Sanofi during the second quarter worth about $51,000. Finally, Mather Group LLC. acquired a new stake in shares of Sanofi during the third quarter worth about $59,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Down 0.4%

Shares of NASDAQ:SNY opened at $44.35 on Tuesday. Sanofi has a fifty-two week low of $43.34 and a fifty-two week high of $60.12. The firm's 50 day moving average price is $47.23 and its 200 day moving average price is $48.40. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The stock has a market cap of $108.17 billion, a price-to-earnings ratio of 12.32, a price-to-earnings-growth ratio of 1.15 and a beta of 0.45.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on SNY shares. Bank of America cut shares of Sanofi from a "buy" rating to a "neutral" rating in a report on Thursday, February 12th. Guggenheim cut shares of Sanofi from a "buy" rating to a "neutral" rating in a research report on Tuesday, December 9th. Citigroup started coverage on shares of Sanofi in a research note on Tuesday, January 27th. They issued a "neutral" rating for the company. Weiss Ratings reiterated a "hold (c)" rating on shares of Sanofi in a research note on Monday, December 29th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Sanofi in a report on Friday, January 16th. Five research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $62.67.

Sanofi Profile

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.